BREYANZI is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: refractory disease to first-line chemoimmunotherapy or relapse within 12 months of ...

The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental ...

The FDA has accepted Bristol Myers Squibb’s Priority Review application for Breyanzi® (lisocabtagene maraleucel) as a ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...

Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the treatment ...

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Breyanzi was previously approved by the U.S. Food and Drug Administration for the treatment of adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy ...

PRINCETON, N.J. — Bristol Myers Squibb (NYSE: BMY) announced the first disclosure of primary analysis results from the high-risk, second-line cohort of TRANSCEND FL, an open-label, global, multicenter ...

Bristol Myers Squibb Canada (BMS) is pleased to announce Health Canada's approval of Breyanzi® (lisocabtagene maraleucel), a type of chimeric antigen receptor T cell (CAR T) therapy, for the ...